• Skip to main content

Hearing Loss Treatment Report

www.HearingLossTreatmentReport.com

Clinical Trial of FX-322 for Age-Related Hearing Loss Is Now ACTIVE

December 17, 2020

Study is no longer recruiting participants. 30 patients enrolled. Half will get a single dose of FX-322, other half will get a placebo. Estimated primary completion date: March 2021. Estimated study completion date: June 2021. Stay tuned…

Link to official study record (last update posted on December 16, 2020):

https://clinicaltrials.gov/ct2/show/NCT04601909

The other recently-added FX-322 study (for severe sensorineural hearing loss) is expected to start before the end of the year, according to a November 16 press release from Frequency Therapeutics.

More updates to follow. Remember to subscribe to the email newsletter, which will begin sending soon. Email michael@urgentresearch.com if you have any comments or feedback.

Email Updates


Powered by Urgent Research

Copyright © 2025 Urgent Research